AstraZeneca stock jumps after surprise lung disease trial win
AstraZeneca’s COPD Breakthrough: A New Dawn for Lung Disease Treatment? AstraZeneca’s stock surged nearly 5% today following the announcement of positive Phase III trial results for tozorakimab, a novel treatment for Chronic Obstructive Pulmonary Disease (COPD). The drug significantly reduced flare-ups in both former and current smokers, marking a potential turning point in the fight … Read more